방사성요오드 불응성 분화갑상선암의 치료, 현재의상황과 향후 전망

Radioiodine refractory differentiated thyroid cancers are rare but they make a definite problem since they runrelentlessly progressive course leading to death in a few years. Recent development of various tyrosine kinaseinhibitors significantly prolonged the overall survival of these patients. Currently available agents are mostlydirected to VEGFR and are not specific to thyroid cancer and their efficacy is somewhat limited for a certain periodof time. Very recently developed specific agents can significantly prolong the overall survival of these patientswithout serious adverse event and probably this kind of precision medicine shall be available to all the patientsin near future but at present successive salvage treatment using different angiogenesis inhibitors may be analternative option. KCI Citation Count: 0